國藥控股(01099.HK)：2024年度歸母淨利潤70.5億元 擬派末期息每股0.68元
格隆匯3月24日丨國藥控股(01099.HK)發佈公吿，截至2024年12月31日止年度，截至報吿期末，集團全年實現營業收入人民幣5845.08億元，同比下降2.02%；歸母淨利潤人民幣70.50億元，同比下降22.14%。報吿期內，營業收入規模和利潤同比有所下降，集團重點推進業務模式優化，強化資源配置效率、完善運營合規管控，推動經營質量的有效提升。同時，集團着力於提升業務管治能力和挖掘業務發展潛力，為中長期合規穩健發展奠定堅實基礎。建議向公司股東派發截至2024年12月31日止年度末期股息每股人民幣0.68元(含税)。
面對政策監管和行業轉型加速推進的巨大挑戰，集團聚焦轉型創新及合規賦能，進一步關注各業務經營利潤、應收週轉和經營性現金流等業績指標，持續優化對於上游供應商及下游終端客户的服務水平和價值創造能力。報吿期內，三個主營業務板塊呈現差異化發展態勢。截至2024年末，集團醫藥分銷板塊收入佔比同比上升1.72個百分點，達到73.16%；器械分銷板塊收入佔比同比下降1.68個百分點，達到19.41%；醫藥零售板塊收入佔比同比增加0.14個百分點，達到5.92%。
2024年度，集團醫藥分銷板塊展現了穩健發展韌性，業務收入達到人民幣4443.65億元，同比增長0.75%，業務經營溢利率較上年同期小幅下降0.26個百分點，為2.74%。報吿期內，集團加大醫藥分銷網絡優化佈局，持續以優質的終端結構為醫藥分銷板塊發展築牢根基，針對區域市場差異化驅動省公司業績出現分化的情況，集團積極調整策略，按不同的區域、發展階段及客户結構，制定差異化發展戰略，提升市場份額。截至報吿期末，江浙滬、北京等重點地區持續加大資源投入，提升資源配置效率，推動市場份額的快速增長。報吿期內，上述地區業務增長表現良好；西北、東北、華中地區持續保持業務規模和行業領先優勢。此外，集團持續優化藥品分銷業務渠道結構，提升面向高等級醫院及零售終端的直銷業務，截至報吿期末，集團直銷業務佔比穩健增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
